Pane wikiwiki
Novo's Kallyope deal shows why differentiated peptide mechanisms matter. Learn what non-incretin obesity peptides demand of discovery chemistry.
He aha ka mea i hana ʻia a me ke kumu e pili ai i kēia manawa

Ua ʻohi ʻo Novo Nordisk i ʻekolu mau waiwai momona o ka wā mua mai Kallyope: hoʻokahi peptide therapeutic a me ʻelua mau moho liʻiliʻi, hōʻike ʻia ma kahi 18 Kepakemapa 2026 LinkedIn post na Jacob Petersen, ʻO Novo ke poʻo o ka noiʻi honua, me ka ʻole o nā huaʻōlelo kālā i hōʻike ʻia (ʻO ka hōʻike a BioSpace e pili ana i ke kūʻai waiwai, 21 Kepakemapa 2026). ʻO ka waiwai alakaʻi, K-554, he peptide non-incretin i hoʻokahi pule i mākaukau IND, me Kallyope e hana ana e hoʻomaka i ka pae 1 a ke kali nei i ka ʻikepili ma ka hapa ʻelua o 2026 (Ka palapala ʻaelike a Fierce Biotech, 18 Kepakemapa 2026).

He mea nui ka wehewehe ʻana ma mua o ka hoʻolaha. Ke kūʻai nei ʻo Novo i nā mīkini peptide ʻokoʻa no ka mea he haiki kāna kumu kūʻai: hui 'Ozempic a me Wegovy kuai hiki aku ma kahi o $32 piliona i ka makahiki i hala, me ka pili 67% o ka huina kuai, oiai ka hui e paa ana 40% o ka mākeke hoʻemi kaumaha e kūʻē iā Eli Lilly 60%, e like me ka hapa nui o ka manao (ʻO Pepeluali o CNBC 2026 ka nānā 'ana i ke kūlana o Novo, 25 Pepeluali 2026). Ua alakaʻi ʻo Novo 2026 e hāʻule ke kūʻai aku a me ka loaʻa kālā 5% i 13%, ʻo ia ka emi ʻana o nā kūʻai makahiki mua mai ia manawa 2017. Ua koi ʻia nā mea kuleana a me nā mea loiloi no kēia ʻano hana pipeline, a ua hiki mai ka pahu Kallyope i hoʻokahi pule ma hope o ka hana ʻana o Novo $1.4 piliona i Orbis Medicines no nā macrocycles.
Ki Takeaway: ʻO BioSpace a me Fierce Biotech e hoʻi i hope i ka hōʻike like ʻo Novo, ʻO ka pou LinkedIn a Petersen. ʻO lākou hoʻokahi kumu i heluhelu ʻelua, ʻaʻole ʻelua mau hōʻoia kūʻokoʻa.
He aha nā Mechanism Peptide ʻokoʻa e koi ai i ka Discovery Chemistry

Hoʻomaka kēlā papa hoʻokō me ka hōʻailona, no ka mea, he maʻalahi ka inoa o nā mīkini peptide ʻokoʻa a he kumukūʻai ke ʻano. A 2026 ʻO ka loiloi mua o nā ʻōnaehana peptide-receptor underexplored papa inoa apelin, specx, METRNL, ʻO ka oxyntomodulin a me ka PYY ma waena o nā mea loaʻa i ʻimi ʻia, a he loiloi ia o ka biology, ʻaʻole helu o nā papahana. ʻO ka hoʻohuli ʻana i kekahi o ia mau mea i alakaʻi, ʻo ia ka peptide analog generation i kūkulu ʻia e like me nā panela: alanine scans, nā hiʻohiʻona kūlana, ʻoki a me nā mana scramble (Ke hoʻomohala nei i kahi Peptide: Nā Papahana Waihona Puke a me nā Kūlana Hoʻokohuka, 2019).
Kakaʻikahi ka lōʻihi o ke ʻano hāʻule. ʻO ka hydrophobicity a me ka hōʻuluʻulu ʻana e hoʻonui i nā piko a luku i ka hoʻihoʻi (PMC, 2008), a ma nā hihia paʻakikī, ua hoʻi hou ka hoʻomaʻemaʻe HPLC o nā peptides hydrophobic lōʻihi ma lalo 1% hua mai, me kēlā me kēia Aβ peptides i hoʻihoʻi ʻia ma 0.7%. Hoʻohui ka nui-disulfide a me ka cyclization-heavy sequences i ka heterogeneity pairing cysteine, no laila hiki i kahi kaula laina pololei ke hāʻawi i ka hāʻawi ʻana i nā huahana maikaʻi ʻole (PMC, 2020).
|
ʻO ka mea e hoʻoholo ai |
|
|---|---|
|
Depsipeptides RP-HPLC maemae (wahi %, 214-220 nm) |
Hoʻohui pū i nā haumia a me nā poʻohiwi hui |
|
ʻIkepili LC-MS (nānā ʻia vs theoretical mass) |
Ke kaʻina hewa a i ʻole Kumukūʻai Kuʻuna Peptide Synthesis ua hala ka hui ʻana |
|
Ka nānā ʻana i ka ʻakika amino ʻO ka Tripeptide Synthesis |
ʻO ka peptide i hoʻonui ʻia e ka wai a me nā paʻakai |
|
Hoʻoholo kūʻē (TFA, acetate, chloride) |
Nā hewa kaulike nui ma ka makemakika dosing |
|
LAL endotoxin (pūʻali koa, ka hana holoholona a i ʻole ka hana sterile wale nō) |
Ka lawe ʻana o Endotoxin |
No ke kōkua: Hōʻike ka palapala mea kūʻai aku i ka mea i hoʻouna ʻia. ʻO ke koho ʻana i ka analog aʻe e pono ai ke ʻano kiʻekiʻe, ka hapa nui a me ka counterion, no ka mea, hoʻoholo ka poʻe inā hiki ke hoʻopaʻa ʻia a i ʻole ka hui ʻana.
He aha nā papahana mua e hana ai i kēia manawa
E mālama i ka hana analog e like me ke ala like, ʻaʻole kahi kaʻina. Holo i ka papa kuhikuhi (alanine, kūlana kūlana, ʻoki a me nā mana scramble) me kāu hana mana nui, no ka mea, mākaukau ʻo IND, pono e hoʻokō ka pōʻai i ka palekana nonclinical a me nā manaʻolana CMC/koʻikoʻi i ka manawa like, me ke kūpaʻa, analytical method and batch history (Peptide ʻO nā peptides i hoʻopaʻa ʻia Kaulana, 2026-04-04). ʻO ka hōʻike ʻana ʻo nā hui ʻanuʻu i hoʻopaneʻe pinepine a mihi: RP-HPLC a i ʻole UPLC wahi pākēneka ma 214–220 nm, LC-MS nānā-versus-theoretical mass, ka nānā ʻana i ka ʻakika amino no ka ʻupena, hoʻoholo kūʻē, a me LAL wale nō kahi e pili ai nā mea pili i nā pūnaewele, holoholona a i ʻole nā kahe hana maʻemaʻe. E laka mua i nā palapala pae ʻāina ma mua o ke kūkulu hou ʻana ma mua o ka hana ʻana.
No nā hui e pono ai ka peptide analog generation ma kēlā pae, Kākoʻo ʻo MOL Changes i ka peptide synthesis maʻamau no ka ʻike mua ʻana me nā kaʻina a hiki i 250 nā ʻakika amino, crude i ≥98% maemae, mg a i kg pālākiō, ʻelima mau ʻano waihona waihona analog, ma mua o 200 hoʻololi, a me kahi palapala hōʻoia no ka ʻike ʻana me ka chromatogram HPLC a me ka ʻikepili spectral mass. ʻO ka lawelawe ʻo Peptide Synthesis maʻamau
Nānā: ʻO kēia ʻatikala no nā kumu ʻike a ʻaʻole ia he ʻōlelo aʻoaʻo olakino. E nīnau i kekahi kauka lapaʻau kūpono ma mua o ka hoʻoholo ʻana i ka lāʻau lapaʻau. Hoʻopuka ʻo MOL Changes ma ke ʻano he mea kūʻai peptide, a ʻo nā kikoʻī hiki i luna e wehewehe i kāna mau lawelawe ponoʻī.
Nīnau pinepine
He aha ke ʻano o ka "non-incretin" i ka hoʻomohala ʻana i ka lāʻau momona?
Hana ʻia kahi peptide obesity non-incretin ma o ke ala olaola ʻē aʻe ma mua o ka GLP-1, GIP, a i ʻole nā mea hoʻokipa glucagon e like me ka semaglutide a me ka tirzepatide target. He mea nui kēlā ʻokoʻa no nā kumu ʻelua. Ka mua, ka hoʻomanawanui: Hoʻopili ʻia nā hopena ʻaoʻao o ka ʻōpū i ka incretin receptor activation, no laila hiki i kekahi ʻano hana ʻē aʻe ke pale aku i ka nausea a me ka luaʻi ʻana e hoʻopau ai. Ka lua, hiki hui: Hiki ke kau ʻia kahi mea hana non-incretin ma luna o kahi lāʻau incretin e kū nei ma mua o ka hoʻokūkū ʻana me ia, e wehe ana i ka hoʻohana hoʻohui i nā mea maʻi i loaʻa i kahi GLP-1.
He aha ka mea e pono ai ʻo IND-ready i kahi pūʻolo peptide CMC?
ʻO ka loaʻa ʻana o kahi hoʻopiʻi lāʻau hou no ka noiʻi ʻana ʻo ia ka kemika, hana hana, a ʻo ka pauku mana e hoʻokumu i kahi ala synthesis reproducible, he moʻolelo maʻemaʻe i wehewehe ʻia, a me kahi hana analytical hōʻike kūpaʻa. Hoʻopili maʻamau ka ʻikena analytical peptide i ka ʻike ma ka spectrometry nuipa, maemae e HPLC, counterion a me ke koena solvent ikepili, a me nā haʻawina hoʻohaʻahaʻa ikaika. Hōʻike ʻia ka CMC a me nā mea nonclinical FDA i ke alakaʻi ponoʻī a ke keʻena no nā hoʻouna noiʻi.
Ua ʻike ʻia nā huaʻōlelo ʻo Novo-Kallyope?
ʻAʻole. ʻAʻole i hōʻike ʻo Novo Nordisk i nā ʻōlelo kālā o ke kūʻai ʻana i ka waiwai, a me ka hōʻike a BioSpace e pili ana i ke kūʻai ʻana i ka waiwai e uhi i ke ʻano o ke kālepa me ke kumu kūʻai ʻole. ʻO ka palapala ʻaelike a Fierce Biotech e waiho pū ana i nā helu mua a me nā helu mile i hōʻike ʻole ʻia. E mālama i kekahi loiloi kikoʻī e hoʻolaha ʻia ana ma ka media media me he mea lā ʻaʻole i hōʻoia ʻia.
He aha nā mea e nānā ai ka poʻe heluhelu?
ʻElua lā. Māhele 1 ʻikepili no nā waiwai i loaʻa i manaʻo ʻia ma ka hapa ʻelua o 2026, ʻo ia ka hoʻāʻo maoli mua o ka unuhi ʻana o ka mīkini non-incretin mai nā hiʻohiʻona preclinical i ka ʻae kanaka.. ʻO ka wā lōʻihi, Mālama nā brand semaglutide i ka palekana o ka mākeke ma ka hapa nui o nā ʻāina ma o ka 2030s mua akā ke alo nei i ka hoʻokūkū patent ma nā ʻāina koho e like me Kanada., no laila, hāiki ka puka hoʻokūkū no ka mea komo ʻokoʻa ke hoʻonui ʻia ka lako maʻamau.
Ka hopena
ʻOi aku ka maikaʻi o ka heluhelu ʻana o ka ʻaelike Novo-Kallyope ma ke ʻano he hōʻailona e pili ana i ka liʻiliʻi: nā mīkini peptide ʻokoʻa, ʻaʻole i hoʻohui ʻia nā analogs GLP-1, ʻo nā mea a nā hoa nui e uku nei e loaʻa. ʻO ka hopena ʻelua no nā papahana mua ʻo ia ka neʻe ʻana o ka bottleneck mai ka biology a i ka hoʻokō kemika. ʻAʻole kōkua ka pahuhopu peptide momona non-incretin i kahi papahana ʻaʻole hiki ke hoʻololi wikiwiki i nā analogs e pane i kāna mau nīnau SAR ponoʻī..
Hoʻoponopono hou kēlā i ka ʻano ma ke ʻano he kaʻina de-risking ma mua o ka hana ma lalo. Nā papahana e palapala i ka maʻemaʻe, ʻike ʻike, a ʻo ka like ʻole o ka lot-to-lot i ka wā mua, ʻo ia ka mea nona ka ʻikepili kūloko e ola i ka nānā ʻana i ka wā e nīnau ai kahi hoa a mea hoʻoponopono i ka hopena o ka hopena..
No laila pōkole ka papa inoa kiaʻi: ʻO ke ala e loaʻa ai nā ʻano hana like ʻole i nā kuʻikahi hahai, a hoʻoponopono inā hiki i kāu loop chemistry ke hoʻomau i ka wikiwiki. Inā ʻo ka pane pololei "ʻaʻole i kēia manawa,"ʻo ka hana aʻe he haʻahaʻa haʻahaʻa. Hiki iā ʻoe ke noi i ka pūʻolo palapala e ʻike ai i ke ʻano o ka QC pae nui i ka hana, a i ʻole e hoʻopaʻa i kahi loiloi kūpono no kahi kaʻina kikoʻī ma mua o ka hana ʻana i kahi ala synthesis.

